Abbreviations: anti-HBc = hepatitis B core Ab; BMT = bone marrow transplantation; CB = cord blood; Cy = cyclosporine; d = days; F = female; FK = FK506; HBV = hepatitis B virus; HSCT = hematopoietic stem cell transplantation; M = male; MMF = mycophenolate mofetil; MTX = methotrexate; PB = peripheral blood.
In Japan, 970000 people (0.63%) are infected with HBV, as estimated by hepatitis B surface Ag (HBsAg) testing in blood donors. 1 HBV reactivation has been reported in 11-86% of allogeneic hematopoietic stem cell transplantation (HSCT) recipients with resolved HBV infection, mainly in those receiving stem cells from an anti-HBs-negative donor, with baseline antiHBs o10 mIU/mL and the development of chronic GvHD (cGvHD), requiring tapering or withdrawal of immunosuppressive therapy to treat GvHD. [2] [3] [4] [5] However, the risk factors for HBV reactivation after HSCT remain unclear. In the present study, we assessed the predictive factors in a cohort of patients with resolved HBV infection who subsequently underwent allogeneic HSCT.
A retrospective review of the HSCT database was performed for patients who underwent allogeneic HSCT between January 2003 and October 2014 at Hamanomachi Hospital. Patients were identified as having resolved HBV infection if they were HBsAg-negative, anti-HBc and/or anti-HBs-positive. No patient had been vaccinated for HBV before and after HSCT. The patients who were not followed up for at least 6 months were excluded from this study. To identify predictors of HBV reactivation after allogenic HSCT, the medical records were reviewed for covariates and outcomes of interest (Tables 1a and 1b Transplant-conditioning regimens were classified as either myeloablative (MA) or reduced intensity (RIC) according to the conditioning agents used. MA regimens typically included cyclophosphamide (Cy) and TBI. The standard RIC regimen included low-dose busulfan and fludarabine. HLA disparity was assessed by serological typing, and donors were considered to be HLA matched if six of six HLA-A, -B and -DRB1 were identical. aGvHD was graded according to the consensus grading system. 6 cGvHD was graded according to the NIH consensus criteria. 7 All HSCT donors were tested for HBsAg, anti-HBs and anti-HBc prior to donation, according to standard blood donation screening procedures in Japan. All HSCT recipients were tested for HBsAg and anti-HBc prior to transplantation. Anti-HBs was also checked routinely, however, four cases were not tested. Potential recipients who were anti-HBc-and/or anti-HBs-positive were also subsequently tested for the HBV viral load and assessed for HBV reactivation after HSCT. HBV reactivation was defined as the development of positive HBsAg and/or HBV DNA after transplantation.
Standard biochemical tests of the liver function were performed at each follow-up visit. Assays for HBsAg and anti-HBs were performed in Hamanomachi Hospital. Measurements of HBsAg were carried out using commercial chemiluminescent immunoassay (CLIA) kits (Architect HBsAg QT, Abbott Japan Co., Ltd, Tokyo, Japan) in the ARCHITECT ANALYSER i2000 (Abbott Japan Co., Ltd) in accordance with the manufacturer's instructions. The sensitivity of the HBsAg assay ranged from 0.05 to 250 IU/mL. Measurements of anti-HBs were carried out using qualitative immunochromatography assay kits (Espline HBsAb-N, Fujirebio, Inc., Tokyo, Japan). Assays for anti-HBc and HBV DNA were performed in a commercial clinical laboratory (SRL, Inc., Tokyo, Japan). Measurements of anti-HBc were performed using CLIA kits (ARCHITECT Anti-HBc II, Abbott Japan Co., Ltd.) in the ARCHITECT ANALYSER i2000 (Abbott Japan Co., Ltd.). Samples with S/CO values ⩾ 1.0 were regarded as positive, and o1.0 were negative for anti-HBc. HBV DNA levels were determined by real-time PCR using the COBAS TaqMan HBV v2.0 (Roche Diagnostics K.K., Tokyo, Japan), which has a detection range of 2.1-9.0 log copies/mL. Continuous variables were compared by the Mann-Whitney U-test. Categorical variables were compared by the χ 2 and Fisher's exact tests. A Cox regression analysis (forward selection method) was used to determine the predictors of the time to HBV reactivation. Candidate covariates included in the multivariate analysis were limited to those closely associated with HBV reactivation (P o0.10). The cumulative incidence of patient survival and HBV reactivation after HSCT were calculated using the Kaplan-Meier method, and the difference was evaluated by the log-rank test. A value of P o0.05 was considered to be statistically significant. Statistical analyses were performed using the SPSS statistics version 23.0 software package (SPSS Inc., Chicago, IL, USA).
Of 519 patients who underwent allogenic HSCT during the study period, 92 had evidence of resolved HBV infection with positive anti-HBc and/or anti-HBs prior to HSCT. Of them, 40 patients were excluded because of death and transfer to another hospital within 6 months, and finally 52 patients who were followed up for at least 6 months were enrolled in this study. The median age was 55 years (range: 25-71 years), and 30 (58%) were men. The median anti-HBc level at the baseline was 3.78 S/CO, and 14 patients (27%) were negative (o1.0 S/CO) for anti-HBc. Anti-HBs was positive in 47 patients (90%). In all 52 cases, HBV DNA levels were undetectable. In this cohort, there were more myeloid disease patients than lymphoid disease patients. Myeloid diseases included 26 patients with AML, 8 with myelodysplastic syndrome (MDS), and 2 with CML. Lymphoid diseases included 6 patients with ALL, 5 with adult T-cell leukemia (ATL), and 4 with malignant lymphoma (ML). The remaining one case was severe aplastic anemia (SAA).
Fourteen of the 52 patients (26.9%) developed post-HSCT HBV reactivation. The median interval between HSCT and the development of HBV reactivation was 15 months (range: 3-68 months). In the univariate analyses, the factors significantly associated with HBV reactivation were the titer of anti-HBc (P o 0.001, Figure 1a ), cGvHD (P = 0.043), and pre-HSCT steroid therapy (P = 0.012; Table 1a ). According to the receiver-operating characteristic curve, the anti-HBc titers were dichotomized by 8.75 S/CO (Figure 1b) . Of all factors, titers of anti-HBc ⩾ 8 S/CO remained as an independent factor predictive of HBV reactivation after HSCT: titers of anti-HBc ⩾ 8 S/CO (hazard ratio (HR), 7.429; 95% confidence interval (95% CI), 2.056-26.842; P = 0.002; Table 1b ). The cumulative rates of HBV reactivation after HSCT at one, three, and five years were 10.8%, 30.6% and 43.9%, respectively. As shown in Figure 1c , the cumulative HBV reactivation rates in patients with titers of anti-HBc ⩾ 8 S/CO at 1, 3 and 5 years were 22.2%, 56.8% and 71.2%, respectively, and significantly higher than in those with titers of anti-HBc o 8 S/CO; 2.9%, 9%, and 22%, respectively (P o0.001).
Anti-HBc is one of the most classical serological markers for HBV infection 8 and has been widely used in the screening of chronic HBV infection combined with HBsAg. However, the clinical significance of quantitative anti-HBc remains unclear. Recently, Yuan et al. 9 proposed that higher anti-HBc levels may predict the response of patients receiving anti-HBV therapies. In addition, Fan et al. 10 reported that the baseline anti-HBc titer is an useful predictor of anti-HBV treatment efficacy in HBeAg-positive CHB patients. Typically, immune control of HBV infection is mediated through HBV-specific cytotoxic T cells, however, B cells also have a role in Ag presentation and viral clearance. 11 In this respect, the anti-HBc level is said to serve as a surrogate marker for the host anti-HBV immune response. 12 A potential mechanism for this association is that native HBcAg particles are released from damaged hepatocytes and provide potent antigenic stimulation to B cells, thus raising the serum anti-HBc levels. Kobayashi et al. 14 reported that the titer of anti-HBc can be a surrogate marker for the HBV DNA assay after HBsAg clearance. They demonstrated that HBV could be detected in the sera of patients with high titers of anti-HBc even after HBsAg clearance. These results of the previous studies are very meaningful in that quantitative anti-HBc may reflect the potential activity of HBV even after HBsAg disappearance. However, further studies are needed to confirm this finding.
In Japanese guideline for preventing HBV reactivation, prophylactic administration of nucleoside analogs to resolved HBV patients is not recommended. In contrast, Hwang and Lok 15 proposed patient stratification according to varying levels of risk. Even in resolved HBV patients, they recommended prophylactic antiviral therapy for patients at a high risk of HBV reactivation, such as chemotherapy for hematological malignancies. As the authors demonstrated, the risk of HBV reactivation can vary even in resolved HBV patients by underlying disease, type of immunosuppressive therapy received and HBV status. From that point of view, the Japanese guideline may admit the progression to the next stage. The limitations of our study were its retrospective design, relatively small sample size, no exact data about the donor serology and the titer of anti-HBs. In addition, we have no suitable answer why 14 patients in all 52 cases (27%) were negative for anti-HBc but positive for anti-HBs without HBV vaccination. However, this is the first report about the importance of anti-HBc titer in HSCT recipients with resolved HBV infection.
In conclusion, titers of anti-HBc ⩾ 8 S/CO was an independent risk factor for HBV reactivation after allogeneic HSCT. Clinicians should remain cautious concerning the risk of HBV reactivation, particularly in this group.
